武汉友芝友医疗科技股份有限公司

What 武汉友芝友医疗科技股份有限公司 does

Wuhan Youmeiyou Medical Technology Co., Ltd. (友芝友医疗, "YZYMed") is a privately held Chinese in vitro diagnostic (IVD) company founded in July 2011 and headquartered in Wuhan Optics Valley (光谷), Hubei Province, China. The company focuses on individualized diagnostics for cardiovascular disease and oncology, operating across five integrated technology platforms: ARMS-PCR fluorescent quantitative PCR, multiplex SNP fluorescent quantitative PCR, the CTCBIOPSY nano-microsieve circulating tumor cell detection platform, chemiluminescence immunoassay, and the RAPID FISH rapid fluorescence in situ hybridization system using oligonucleotide probes that reduce hybridization time from the industry-standard 16+ hours to 1-2 hours. YZYMed has developed approximately 160+ gene diagnostic products, holds 19-22 NMPA Class III medical device registrations spanning pharmacogenomics (SLCO1B1, ApoE, CYP2C19, CYP2D6, CYP2C9, VKORC1, MTHFR, ALDH2, HLA-B*5801, and a hypertension panel covering AGTR1, ACE, ADRB1), tumor companion diagnostics (EGFR, KRAS, NRAS, PIK3CA, ROS1, EML4-ALK, HER2, BCR/ABL, AML1/ETO), and methylation-based screening (SDC2 for colorectal cancer), and has secured 110+ CE certifications plus Pakistan DRAP approvals for international market access.

The company generates revenue through one-time sale of NMPA Class III molecular diagnostic reagent kits to hospitals, sale of FISH detection products (reagent kits and automated F900/F901/F902 processing systems), and CTC detection equipment (CTCBIOPSY D200/A10/D800 instrument family) plus consumables, supplemented by pharmacogenomic testing service fees. Per-test pricing for CTC detection averages 2,000-3,000 RMB in the Chinese market. YZYMed's go-to-motion is direct enterprise field sales to large tier-3A hospital accounts (600+ hospitals in China), supported by regional distributors, a specialized pathology sales team, and a dedicated international sales division serving Pakistan, Southeast Asia, the Middle East, South America, Africa, Turkey, Thailand, and Germany. The company claims #1 market share in cardiovascular pharmacogenomic testing in China, with cumulative tests exceeding 1.5 million patients and 100,000+ CTC patient tests via the CTCBIOPSY system deployed across 100+ tier-3 hospitals.

YZYMed's strategic positioning combines a differentiated proprietary technology stack (the only CTC platform clinically differentiating single CTCs, circulating tumor microemboli (CTM), and neutrophil CTC subtypes; oligonucleotide FISH platform versus traditional BAC cloning) with deep regulatory moat (multiple Class III approvals), substantial clinical evidence base (publications in Cancer Cell International, International Journal of Cancer, Clin Transl Med IF=10.6), and an academic KOL network anchored by Academician Zhou Honghao (recognized founder of China's individualized medicine discipline) and Prof. Liu Kan (CTC technology advisor). The 2026 strategic partnership with Leica Biosystems represents a significant channel expansion into the broader pathology market. Five consecutive years (2020-2024) on the Donghu Hi-Tech Zone "Gold Seed" IPO candidate list indicate active preparation for a potential public listing.

Name

武汉友芝友医疗科技股份有限公司

Legal name

武汉友芝友医疗科技股份有限公司

Website

https://yzymedical.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Wuhan Youmeiyou Medical Technology (YZYMed) is a privately held Chinese IVD company developing NMPA Class III pharmacogenomic kits, CTCBIOPSY liquid biopsy instruments, and RAPID FISH reagents for cardiovascular drug guidance and oncology companion diagnostics, serving 600+ tier-3A hospitals in China plus select international markets across Pakistan, Southeast Asia, and Europe.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics (In Vitro Diagnostics)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Molecular diagnostics
• Pharmacogenomics testing
• Circulating tumor cell detection
• Fluorescence in situ hybridization
• Companion diagnostics

Headquarters

HQ city

武汉市, 湖北省

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Molecular Diagnostic Reagents (NMPA Class III Registered): Sale of NMPA-approved Class III molecular diagnostic reagent kits for pharmacogenomics (SLCO1B1&ApoE, CYP2C19, CYP2D6, MTHFR, ALDH2, CYP2C9&VKORC1, HLA-B*5801, hypertension panel) and tumor companion diagnostics (EGFR, KRAS, NRAS, PIK3CA, ROS1, EML4-ALK). Revenue is one-time per test, recurring through hospital re-orders.
2. FISH Detection Products: Sale of fluorescence in situ hybridization probe kits (HER2, BCR/ABL, AML1/ETO, ALK, BCL2, etc.) and FISH automation equipment (F900, F901, F902). Revenue is one-time with consumable replenishment.
3. CTC Detection Equipment & Consumables: Sale and service of CTCBIOPSY CTC separation instruments (D200, A10, D800) along with dedicated consumables for CTC enrichment and identification. Provides both capital equipment and recurring consumable revenue.
4. Pharmacogenomics Testing Services: The company provides gene detection kits to hospitals; hospitals perform tests and charge patients. The company also provides related testing services through clinical channels, generating revenue from kit sales and service fees. Cumulative testing exceeds 1.5 million patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

友芝友医疗 (YZYMed) develops, manufactures, and sells NMPA Class III-registered in vitro diagnostic reagent kits and instrumentation for precision medicine. The company's product portfolio covers pharmacogenomics testing kits for individualized cardiovascular and oncology drug therapy (SLCO1B1&ApoE, CYP2C19, CYP2D6, MTHFR, ALDH2, HLA-B*5801, hypertension panels), tumor companion diagnostics (EGFR, KRAS, NRAS, PIK3CA, ROS1, EML4-ALK), FISH reagent kits (HER2, BCR/ABL, AML1/ETO, ALK), and SDC2 methylation kits for colorectal cancer screening, alongside the proprietary CTCBIOPSY liquid biopsy platform for circulating tumor cell detection and the RAPID FISH automated slide processing system. Products are sold to tier-3A hospitals in China and international markets, with cumulative testing exceeding 1.5 million patients.

Product overview

YZYMed operates as a diversified in vitro diagnostic (IVD) product portfolio company covering four major product lines: (1) Tumor targeted companion diagnostics — ARMS-PCR and multi-SNP qPCR reagent kits for KRAS, PIK3CA, NRAS, EGFR, ROS1, EML4-ALK and other oncogenes; (2) Pharmacogenomics products — a comprehensive panel of Class III NMPA-registered PCR-fluorescent probe kits covering SLCO1B1, ApoE, CYP2C19, CYP2D6, CYP2C9, VKORC1, MTHFR, ALDH2, HLA-B*5801, and hypertension-related genes (AGTR1, ACE, ADRB1) for individualized cardiovascular and antihypertensive drug therapy; (3) CTCBIOPSY liquid biopsy system — a nano-microsieve-based CTC/CTM capture and identification platform comprising D200 (integrated cell separation/staining), A10 (automated CTC separation), and D800 (automated scanning/AI identification) instruments for cancer early warning and MRD monitoring; and (4) FISH product line — rapid oligonucleotide probe FISH reagents (HER2, ALK, BCR/ABL, AML1/ETO, BCL2) achieving 1-2 hour hybridization, supported by automated FISH slide processing systems (F900/F901/F902). The company also offers chemiluminescence immunoassay reagents. In total, YZYMed has developed 160+ gene diagnostic products and multiple IVD instruments, with 19 molecular diagnostic reagent kits holding NMPA Class III registration and 110+ products with CE certification.

Differentiator

Problem solved

Functional benefit

Brands

• CTCBIOPSY: 循环肿瘤细胞检测系统，芝友医疗自主研发的CTC分离检测平台，已获NMPA认证。
• RAPID FISH

Products and services

• Tumor Companion Diagnostics (肿瘤靶向伴随诊断产品)

Quantifiable outcome

• Statin adverse reaction risk 10x higher in Chinese patients vs. Caucasians (HPS2-THRIVE 2013 study), underscoring clinical need for SLCO1B1/ApoE pharmacogenomic testing
• +6 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and major.

• 徕卡生物科技（上海）有限公司 (Leica Biosystems Shanghai)coreStrategic or Co-development Partner · 24 April 2026芝友医疗与徕卡生物科技于2026年4月24日正式签署战略合作协议，在'2026中华医学会病理学分会第三十一次学术会议'期间宣布。双方将深度融合各自在荧光原位杂交(FISH)技术平台和徕卡在病理全流程自动化解决方案的领先优势，共同推进精准医疗技术的创新突破与临床拓展。合作建立在双方过去一年富有成效的协作基础之上，徕卡在自动化设备及工作流程优化方面的领先能力与芝友医疗在FISH探针开发及快速杂交技术上的核心优势形成高度互补，共同响应国家医疗卫生强基工程，推动精准诊疗技术下沉基层。
• 同济医院 (Tongji Hospital, Tongji Medical College)majorStrategic or Co-development Partner · 31 October 2024同济医院胸外科专家付圣灵教授与芝友医疗开展深度合作，探索CTC检测技术在微小残留病灶(MRD)检测中的应用，特别是在早期肺癌的临床应用。双方共同设计研究方案，收集分析患者数据，评估CTC技术在胸外科早期肺癌中的应用效果，并就技术开发及优化进行深入合作。
• 江苏省人民医院/南京医科大学第一附属医院coreStrategic or Co-development Partner · 4 April 2018联合成立'加拿大白求恩医学基金会江苏省人民医院肿瘤分子诊断暨循环肿瘤细胞活检研究中心'。该中心致力于CTC检测技术在肺癌、乳腺癌、前列腺癌、胃肠癌、肝癌等常见实体肿瘤的临床研究，并拓展在脑胶质瘤、骨肉瘤、鼻咽癌等癌种的CTC临床研究。研究中心还与美国MD Anderson Cancer Center、加拿大白求恩医学基金会、多伦多大学医学院、麦吉尔医学院等国际机构建立学术交流合作。
• 武汉大学人民医院coreStrategic or Co-development Partner · 1 January 2018武汉大学人民医院牵头、芝友医疗参与研究的《人脑胶质瘤精准诊疗及临床推广应用》项目荣获湖北省科学技术成果推广二等奖。芝友医疗CTCBIOPSY系统在脑胶质瘤CTC检测中积累了大量临床数据，检出率达85%以上，研究成果发表在Clin Transl Med (IF=10.6)等权威期刊。
• 武汉协和医院 (Wuhan Union Hospital)coreStrategic or Co-development Partner武汉协和医院肿瘤中心张涛教授团队与芝友医疗研发部合作，基于CTCBIOPSY平台对98名结直肠癌化疗患者进行CTC/CTM计数研究和分子分型研究，历时5年随访。研究成果发表在Cancer Cell International和International Journal of Cancer等国际期刊，首次揭示间质型CTC/CTM与结直肠癌患者预后关联性，确立了CTC/CTM分型的临床价值。
• 周宏灏 院士 (Academician Zhou Honghao)coreOthers中国工程院院士、个体化医学奠基人、遗传药理学和药物基因组学学科开拓者担任公司首席科学顾问。周院士同时领衔推动中南大学湘雅医学院与无锡国家生命科学园共建亚洲最大基因检测产业基地项目（总投资5亿元）。
• 刘侃 教授 (Prof. Liu Kan)coreOthers武汉纺织大学电子与电气工程学院院长、湖北省海外高层次引进人才、楚天学者计划人才，CTC技术顾问。曾任公司研发副总裁，组建友芝友微纳医学研究中心并担任CTC检测设备研发项目负责人。
• 武汉纺织大学 (Wuhan Textile University)majorStrategic or Co-development PartnerAcademic collaboration with Prof. Liu Kan's team at Wuhan Textile University's School of Electronics and Electrical Engineering for CTC technology R&D. Prof. Liu Kan led multiple national-level R&D projects including National Natural Science Foundation projects and key R&D programs.
• 加拿大白求恩医学基金会 (Bethune Medical Foundation Canada)majorStrategic or Co-development PartnerInternational foundation facilitating academic exchange between Chinese and Canadian medical institutions. Founded in 2015, the foundation connects Canadian institutions (University of Toronto, McGill University) with Chinese partners for liquid biopsy and molecular diagnostics research, including the joint CTC research center at Jiangsu Provincial People's Hospital.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Genetron Health: Chinese precision oncology company specializing in NGS-based tumor profiling, liquid biopsy, and early cancer screening. Comparable in oncology companion diagnostics and CTC/liquid biopsy applications but with NGS approach vs YZYMed's nano-microsieve CTC and PCR-based PGx platforms.
• Berry Genomics: Chinese genomics and liquid biopsy company with NIPT, oncology NGS, and CTC detection capabilities. Comparable in liquid biopsy/early cancer detection (CRC screening, MRD monitoring) where YZYMed's CTCBIOPSY and SDC2 methylation products compete, with stronger international distribution network.
• Burning Rock Biotech: Chinese oncology-focused NGS company providing liquid biopsy and tissue-based companion diagnostics for cancer therapy selection. Comparable in CTC/liquid biopsy and tumor companion diagnostics but with NGS technology focus rather than YZYMed's PCR/FISH approach, and well-capitalized Nasdaq-listed competitor.

Direct peers

• Da An Gene (Da An Clinical Laboratories Center): Major Chinese molecular diagnostics and IVD manufacturer with broad reagent portfolio including PCR kits for infectious disease, tumor markers, and PGx. Comparable as a diversified Chinese IVD company with hospital-direct distribution and similar regulatory positioning in NMPA Class III products.
• Lepu Diagnostics: Chinese cardiovascular-focused medical device and IVD company providing diagnostic reagents, equipment, and consumables to cardiology departments. Direct overlap with YZYMed's cardiovascular pharmacogenomics franchise (SLCO1B1, ApoE, CYP2C19) and similar tier-3 hospital channel.
• Amoy Diagnostics: Chinese molecular diagnostics company specializing in oncology companion diagnostics (EGFR, KRAS, ALK, ROS1) using PCR and FISH technologies. Most direct competitor to YZYMed's tumor companion diagnostics and FISH product lines, serving similar tier-3 hospital oncology and pathology departments.
• Tellgen (Shanghai Tellgen Life Science): Chinese molecular diagnostics company with focus on pharmacogenomics testing reagents, including CYP2C19, CYP2C9, VKORC1, and HLA-B*5801 — directly overlapping with YZYMed's PGx portfolio. Comparable NMPA Class III strategy and tier-3 hospital customer base.

Broad incumbents

• Mindray: Largest Chinese IVD and medical device company with extensive IVD reagent and instrument portfolio across clinical chemistry, immunoassay, hematology, and molecular diagnostics. Broad incumbent overlapping with YZYMed's CTC instruments (D200/A10/D800), FISH automation (F900/F901/F902), and chemiluminescence platforms.
• Autobio Diagnostics: Major Chinese IVD company specializing in chemiluminescence immunoassay, microbiology, and clinical chemistry reagents and instruments. Comparable as a Chinese IVD manufacturer with hospital-direct sales model and broad product portfolio that could expand into molecular diagnostics segments where YZYMed competes.
• BGI Genomics: Large Chinese genomics and IVD company offering broad molecular diagnostics, NIPT, oncology NGS, and pathology testing services. Broadly comparable across multiple YZYMed product categories but at substantially larger scale, with established international footprint and broader reimbursement coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E6%AD%A6%E6%B1%89%E5%8F%8B%E8%8A%9D%E5%8F%8B%E5%8C%BB%E7%96%97%E7%A7%91%E6%8A%80%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 武汉友芝友医疗科技股份有限公司